Jerzy Jankun

List of Publications by Year in descending order

82 papers	2,441 citations	279798 23 h-index	223800 46 g-index
83 all docs	83 docs citations	83 times ranked	3141 citing authors

#	Article	IF	Citations
1	Why drinking green tea could prevent cancer. Nature, 1997, 387, 561-561.	27.8	656
2	Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence.. International Journal of Molecular Medicine, 2000, 6, 521-6.	4.0	104
3	Determining whether curcumin degradation/condensation is actually bioactivation (Review). International Journal of Molecular Medicine, 2016, 37, 1151-1158.	4.0	92
4	Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Journal of Cellular Biochemistry, 1993, 53, 135-144.	2.6	87
5	A study of the anti-diabetic agents of camel milk. International Journal of Molecular Medicine, 2012, 30, 585-592.	4.0	82
6	Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X-ray structure at 2.1 Ã... resolution. Proteins: Structure, Function and Bioinformatics, 2003, 54, 13-19.	2.6	72
7	Plasminogen activator inhibitor-1 in kidney pathology. International Journal of Molecular Medicine, 2013, 31, 503-510.	4.0	65
8	Human Platelet 12-Lipoxygenase, New Findings about Its Activity, Membrane Binding and Low-resolution Structure. Journal of Molecular Biology, 2008, 376, 193-209.	4.2	63
9	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 A reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. International Journal of Molecular Medicine, 2003, 12, 415-20.	4.0	54
10	Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU International, 2005, 95, 1237-1244.	2.5	53
11	Structure of curcumin in complex with lipoxygenase and its significance in cancer. International Journal of Molecular Medicine, 2003, 12, 17-24.	4.0	52
12	Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Molecular Cancer Therapeutics, 2006, 5, 1371-1382.	4.1	51
13	Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncology Reports, 2001, 8, 463-70.	2.6	43
14	Clinical implications of the growth-suppressive effects of chlorhexidine at low and high concentrations on human gingival fibroblasts and changes in morphology. International Journal of Molecular Medicine, 2016, 37, 1594-1600.	4.0	40
15	Probing Dimerization and Structural Flexibility of Mammalian Lipoxygenases by Small-Angle X-ray Scattering. Journal of Molecular Biology, 2011, 409, 654-668.	4.2	37
16	Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.. Oncology Reports, 1999, 6, 523-6.	2.6	37
17	OPTICAL CHARACTERISTICS OF THE CANINE PROSTATE AT 665 NM SENSITIZED WITH TIN ETIOPURPURIN DICHLORIDE: NEED FOR REAL-TIME MONITORING OF PHOTODYNAMIC THERAPY. Journal of Urology, 2004, 172, 739-743.	0.4	35
18	Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate, 2006, 66, 779-787.	2.3	31

#	Article	IF	Citations
19	Structural and Thermochemical Characterization of Lipoxygenaseâ^'Catechol Complexesâ€. Biochemistry, 1998, 37, 17952-17957.	2.5	29
20	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Ã... reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. International Journal of Molecular Medicine, 2003, 12, 415.	4.0	27
21	Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development. Current Enzyme Inhibition, 2007, 3, 119-132.	0.4	26
22	Soybean lipoxygenase-3 in complex with 4-nitrocatechol. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 613-615.	2.5	25
23	Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). International Journal of Molecular Medicine, 2011, 29, 3-11.	4.0	23
24	Computer Model for Cryosurgery of the Prostate. Computer Aided Surgery, 1999, 4, 193-199.	1.8	22
25	Transperinealin vivofluence-rate dosimetry in the canine prostate during SnET2-mediated PDT. Physics in Medicine and Biology, 2004, 49, 3209-3225.	3.0	22
26	Unusual clotting dynamics of plasma supplemented with iron(III). International Journal of Molecular Medicine, 2014, 33, 367-372.	4.0	22
27	Theaflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity?. International Journal of Molecular Medicine, 2010, 26, 45-50.	4.0	21
28	The plasminogen activation system in periodontal tissue (Review). International Journal of Molecular Medicine, 2014, 33, 763-768.	4.0	21
29	Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). International Journal of Molecular Medicine, 2004, 13, 759-66.	4.0	21
30	Structure of curcumin in complex with lipoxygenase and its significance in cancer. International Journal of Molecular Medicine, 2003, 12, 17.	4.0	20
31	Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives. Oncology Letters, 2014, 7, 17-22.	1.8	20
32	Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review). International Journal of Molecular Medicine, 2019, 43, 15-25.	4.0	20
33	Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncology Reports, 2012, 28, 1275-1282.	2.6	19
34	Formulation and characterization of EGCG for the treatment of superficial bladder cancer. International Journal of Molecular Medicine, 2017, 40, 329-336.	4.0	19
35	Human platelet 12-lipoxygenase: Naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior. International Journal of Molecular Medicine, 2009, 24, 759-64.	4.0	17
36	Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. International Journal of Oncology, 2014, 44, 147-152.	3.3	17

#	Article	IF	Citations
37	Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?. International Journal of Molecular Sciences, 2018, 19, 248.	4.1	17
38	Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. Oncology Reports, 2006, 16, 341-6.	2.6	17
39	Very long halfâ€life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model. BJU International, 2010, 105, 1469-1476.	2.5	16
40	Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. International Journal of Molecular Medicine, 2011, 27, 525-9.	4.0	16
41	Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. International Journal of Molecular Medicine, 2011, 29, 61-4.	4.0	16
42	COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs.. Translation the University of Toledo Journal of Medical Sciences, 0, 7, 1-5.	0.0	16
43	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. International Journal of Molecular Medicine, 2007, 20, 683-7.	4.0	16
44	Enamel matrix proteins exhibit growth factor activity: A review of evidence at the cellular and molecular levels. Experimental and Therapeutic Medicine, 2015, 9, 2025-2033.	1.8	14
45	Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacological Reports, 2009, 61, 673-680.	3.3	13
46	Experimental immunology Complex function of magnesium in blood clot formation and lysis. Central-European Journal of Immunology, 2013, 2, 149-153.	1.2	13
47	A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Molecular Cancer Therapeutics, 2003, 2, 19-28.	4.1	13
48	Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. International Journal of Molecular Medicine, 2010, 26, 501-4.	4.0	12
49	Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. Experimental and Therapeutic Medicine, 2010, 1, 575-577.	1.8	12
50	Experimental immunology Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells. Central-European Journal of Immunology, 2015, 1, 1-4.	1.2	12
51	Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). International Journal of Molecular Medicine, 2004, 13, 759.	4.0	11
52	An Energy-Based Segmentation of Prostate from Ultrasouind Images using Dot-Pattern Select Cells. , 2007, , .		11
53	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. International Journal of Molecular Medicine, 0, , .	4.0	11
54	Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Experimental and Therapeutic Medicine, 2015, 9, 2339-2343.	1.8	11

#	Article	IF	Citations
55	Effects of chlorhexidine, essential oils and herbal medicines (Salvia, Chamomile, Calendula) on human fibroblast in vitro. Central-European Journal of Immunology, 2016, 2, 125-131.	1.2	11
56	Yin and yang of the plasminogen activator inhibitor. , 2009, 119, 410-7.		11
57	Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review). International Journal of Oncology, 2015, 47, 16-24.	3.3	10
58	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. International Journal of Molecular Medicine, 2007, 20, 11-20.	4.0	10
59	Computer model for photodynamic therapy of the prostate. , 2000, 3907, 222.		9
60	Do Human Lipoxygenases have a PDZ Regulatory Domain?. Current Molecular Medicine, 2008, 8, 768-773.	1.3	9
61	Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-7.	1.9	9
62	Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. International Journal of Molecular Medicine, 2003, 11, 287-91.	4.0	8
63	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports, 0, , .	2.6	7
64	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports, 2004, 12, 1155-62.	2.6	7
65	Nutraceutical inhibitors of urokinase: Potential applications in prostate cancer prevention and treatment. Oncology Reports, 2006, 16, 341.	2.6	6
66	Protein-based nanotechnology: Antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy. International Journal of Oncology, 2011, 39, 949-53.	3.3	6
67	Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report. Experimental and Therapeutic Medicine, 2012, 4, 661-664.	1.8	6
68	Isolation and characterization of serum albumin from Camelus dromedarius. Experimental and Therapeutic Medicine, 2013, 6, 519-524.	1.8	6
69	Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 144-150.	0.7	6
70	Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products. International Journal of Molecular Medicine, 2013, 31, 1153-1158.	4.0	5
71	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. International Journal of Molecular Medicine, 2006, 17, 437-47.	4.0	5
72	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. International Journal of Molecular Medicine, 2006, 17, 437.	4.0	4

#	Article	IF	Citations
73	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. International Journal of Molecular Medicine, 2007, 20, 11.	4.0	4
74	A thousand words about the challenges of photodynamic therapy. Journal of Medical Science, 2019, 88, 195-199.	0.7	4
75	The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. Wspolczesna Onkologia, 2013, 4, 389-393.	1.4	2
76	Platelet 12-lipoxygenase and stem cells in Barrettâ€™s esophagus. Oncology Letters, 2010, 1, 789-791.	1.8	1
77	Application of Long-Acting VLHL PAI-1 during Sutureless Partial Nephrectomy in Mice Reduces Bleeding. BioMed Research International, 2015, 2015, 1-7.	1.9	1
78	Targeting of Drugs to Tumors: The Use of the Plasminogen Activator Inhibitor as a Ligand. , 1994, , 67-79.		1
79	VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. International Journal of Molecular Medicine, 2009, 23, 57-63.	4.0	1
80	Control of the Aggressive Capacity of Prostate Cancer by Nutritional Inhibitors of Urokinase and Lipoxygenase. International Journal of Human Genetics, 2003, 3, 127-134.	0.1	0
81	Can components of the plasminogen activation system predict the outcome of kidney transplants?. Central-European Journal of Immunology, 2018, 43, 222-230.	1.2	0
82	If Nature Failed Creating the Perfect Prostate Could Inhibitors of Proteolysis Help?. , 2013, 02, .		0